Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Luspatercept plus azacitidine in intermediate- and high-risk myelodysplastic syndromes
ChiCTR2500104329Phase 2Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jun 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of luspatercept and azacitidine in myelodysplastic syndrome (MDS), sponsored by West China Hospital of Sichuan University. Primary endpoints: Complete remission rate in bone marrow and Red blood cell transfusion independence ≥ 8 weeks. Started Jun 2025; status: recruiting.
02
Drugs
luspaterceptazacitidine
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on ChiCTR2500104329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500104329.